U.S. COMPANY FILING
Edwards Lifesciences Corp — Form 10-K filed 2026-02-25
Filing text preview
Edwards Lifesciences reported 2025 net sales of $6.07 billion, up 11.5% YoY, but continuing ops net income fell 24.4% to $1.06 billion due to litigation costs, impairments, and the terminated JenaValve acquisition. The company completed the sale of its non-core product group and repurchased shares.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record